What Are Cognitive Research Peptides?
Cognitive research peptides are structurally characterized synthetic compounds evaluated in preclinical and in vitro models for neuromodulatory properties. Semax, Selank, and Dihexa represent three mechanistically distinct compound classes: an ACTH-derived fragment analog, a tuftsin-derived immunomodulatory peptide, and an angiotensin IV analog, respectively. Each has been characterized in published literature for effects on neurotrophin expression, receptor modulation, and synaptogenic signaling — representing targeted molecular tools for interrogating discrete CNS pathways. Research interest in these compounds derives from their receptor selectivity: neurotrophic receptor systems, inhibitory neurotransmitter receptors, and receptor tyrosine kinase cascades each represent well-defined pharmacological targets that enable mechanistically controlled experimental designs. All three are evaluated for research purposes only. Evo Amino supplies research-grade preparations of each compound intended exclusively for laboratory and preclinical investigation. The published literature base spans neuroprotection models, anxiety-related behavioral paradigms, and synaptic plasticity characterization in cell culture systems.
How Does Semax Modulate BDNF and Cognitive Research Models?
Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone fragment ACTH(4-7), extended at the C-terminus with a Pro-Gly-Pro sequence. Its full sequence is Met-Glu-His-Phe-Pro-Gly-Pro, sometimes designated MNPAF in abbreviated notation. Published research has characterized Semax's capacity to upregulate brain-derived neurotrophic factor (BDNF) expression in neuronal cell cultures and rodent brain tissue models. Ashmarin et al. investigated Semax-induced BDNF elevation and downstream TrkB receptor activation in neuronal preparations [PMID: 16445185]. Medvedeva et al. examined gene expression profiles following Semax exposure in brain tissue models, identifying transcriptional changes in multiple neurotrophic pathways [PMID: 18841466]. The peptide's ACTH(4-7) core is thought to interact with melanocortin receptors, with downstream BDNF induction proposed as a secondary consequence of melanocortin receptor engagement. The Pro-Gly-Pro C-terminal extension appears to contribute to metabolic stability and may modulate receptor binding kinetics relative to the unextended ACTH(4-7) fragment. These findings position Semax as a research tool for studying neurotrophin regulation in neuroprotection and cognitive function models. All research applications use this compound for preclinical purposes only.
What Is the Anxiolytic Mechanism of Selank in Research?
Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory tetrapeptide tuftsin, extended with Gly-Pro-Lys at the C-terminus. Its amino acid sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, with molecular formula C₄₆H₇₃N₁₃O₁₃ and molecular weight 1046.2 g/mol. Published research has characterized Selank as an allosteric modulator of GABA-A receptors in neuronal preparations. Kozlovskaya et al. described Selank's effects on GABA-A receptor subunit composition and chloride channel conductance in cell culture models [PMID: 22786332]. Kozlovsky et al. investigated Selank's influence on enkephalin system activity and neurotransmitter expression profiles in brain tissue preparations, identifying interactions with opioid receptor pathways [PMID: 22968004]. Uchakina et al. examined Selank's immunomodulatory properties, including modulation of interleukin expression in immune cell cultures [PMID: 20717095]. In animal models, Selank has demonstrated anxiolytic-like behavioral outcomes in elevated plus maze and open field paradigms. These behavioral effects appear mechanistically linked to GABA-A allosteric modulation and enkephalin system engagement — a dual-pathway profile that distinguishes Selank from classical benzodiazepines in the published literature. All findings are from preclinical and in vitro research; Selank is supplied for research purposes only.
How Does Dihexa Activate HGF/c-Met Signaling Pathways?
Dihexa (also designated PNB-0408) is a synthetic hexapeptide analog of angiotensin IV, developed as a potent agonist of the hepatocyte growth factor (HGF) and its receptor c-Met. Its structure originates from angiotensin IV modifications that enhance binding affinity at the HGF/c-Met receptor complex — a receptor tyrosine kinase pathway with documented roles in neuronal survival, synaptic plasticity, and axonal growth. Published research by McCoy et al. demonstrated that Dihexa binds HGF with high affinity and transactivates c-Met signaling cascades in hippocampal preparations, producing synaptogenic effects in neuronal cultures [PMID: 23090578]. Bhatt et al. investigated the synaptogenic properties of Dihexa in rodent models, observing increases in synaptic density markers in hippocampal tissue [PMID: 23548006]. Downstream HGF/c-Met signaling activates PI3K/Akt and MAPK/ERK cascades associated with neuronal survival and synaptic remodeling. The angiotensin IV scaffold of Dihexa provides the structural basis for its high potency relative to endogenous HGF in receptor activation assays — a potency advantage documented in the picomolar affinity range for HGF binding. Wright et al. characterized the angiotensin IV binding site and its role in cognitive function in rodent models, establishing foundational context for subsequent c-Met-directed analogs including Dihexa [PMID: 20888304]. Published findings identify Dihexa as a research probe for studying synaptogenesis and c-Met-dependent neuroprotection. All applications are for preclinical research only.
Comparison Table
| Compound | Origin | Mechanism | Receptor Target | Molecular Weight | Primary Research Application | Key PMIDs |
|---|---|---|---|---|---|---|
| Semax | ACTH(4-7) analog | BDNF upregulation | TrkB (indirect) | 813 Da | Neuroprotection, cognitive studies | 16445185, 18841466 |
| Selank | Tuftsin analog | GABA-A modulation, enkephalin | GABA-A, opioid receptors | 751 Da | Anxiolytic research, stress response | 22786332, 22968004, 20717095 |
| Dihexa | Angiotensin IV analog | HGF/c-Met agonism | c-Met | 811 Da | Synaptogenesis, cognitive enhancement research | 23090578, 23548006 |
What Does Published Research Show About Each Compound?
Published literature on Semax centers on BDNF elevation and neuroprotective gene expression changes in neuronal and brain tissue models. Ashmarin et al. documented BDNF induction and TrkB activation in neuronal cultures [PMID: 16445185], while Medvedeva et al. identified broad transcriptional changes in neurotrophic factor networks using gene expression array approaches [PMID: 18841466]. For Selank, Kozlovskaya et al. established GABA-A receptor allosteric modulation as a primary mechanism [PMID: 22786332], with Kozlovsky et al. reporting additional effects on enkephalin system activity that extend its mechanistic profile beyond GABAergic signaling [PMID: 22968004]. Dihexa research by McCoy et al. and Bhatt et al. demonstrates potent HGF/c-Met transactivation and downstream synaptogenic outcomes in hippocampal models [PMID: 23090578] [PMID: 23548006]. Across all three compounds, published findings derive from cell culture systems and rodent preclinical models — no clinical efficacy claims are supported by this literature in the context of research-grade compound supply. Evo Amino provides each compound strictly for laboratory investigation, with HPLC purity verification and mass spectrometry identity confirmation on every batch.
Frequently Asked Questions
What distinguishes Semax from other ACTH-derived peptides in research?
Semax is distinguished from other ACTH-derived peptides by its specific core sequence ACTH(4-7), designated Met-Glu-His-Phe, extended with a C-terminal Pro-Gly-Pro tripeptide that enhances metabolic stability and may influence receptor binding kinetics. Most ACTH fragment analogs studied in the literature target melanocortin receptor subtypes and modulate stress-axis signaling. Semax's profile is distinct in that published research documents secondary induction of BDNF and activation of TrkB-dependent neurotrophic signaling, rather than direct adrenocortical axis effects [PMID: 16445185]. This BDNF-upregulating property is not consistently reported for other ACTH fragment analogs such as ACTH(1-24) or alpha-MSH. Medvedeva et al. further demonstrated that Semax modulates broader gene expression networks related to neuroplasticity [PMID: 18841466]. The Pro-Gly-Pro extension appears central to Semax's differentiated pharmacological profile in rodent models and neuronal cell culture systems. All characterization is from preclinical research; Semax is supplied for research purposes only by Evo Amino.
How is Selank's mechanism of action different from synthetic benzodiazepines in research models?
Selank and synthetic benzodiazepines both interact with GABA-A receptors, but their binding sites and functional consequences differ in published research models. Classical benzodiazepines bind to the benzodiazepine site at the alpha/gamma subunit interface, producing positive allosteric modulation and increasing chloride conductance. Selank's GABA-A receptor interaction, characterized by Kozlovskaya et al., is described as allosteric modulation with distinct subunit selectivity that differs from the benzodiazepine binding profile [PMID: 22786332]. Selank additionally engages enkephalin system pathways — an interaction not associated with classical benzodiazepines in published models [PMID: 22968004]. The tuftsin-derived immunomodulatory scaffold adds a third mechanistic dimension: Uchakina et al. documented effects on interleukin expression in immune cell cultures [PMID: 20717095]. These mechanistic features collectively make Selank useful in research designs requiring GABA-A modulation in the absence of full benzodiazepine receptor occupancy and its associated confounding effects. Selank is available from Evo Amino for research purposes only.
What is the significance of HGF/c-Met signaling in Dihexa research?
HGF/c-Met signaling is a receptor tyrosine kinase pathway governing neuronal survival, synaptic plasticity, and axonal growth in the central nervous system. Dihexa's research significance lies in its capacity to act as a potent HGF mimetic that transactivates c-Met receptors independently of the endogenous HGF ligand — a property that enables researchers to interrogate c-Met pathway contributions without the pleiotropic effects of the full HGF protein. McCoy et al. demonstrated that Dihexa binds HGF with picomolar affinity and activates downstream c-Met phosphorylation in hippocampal tissue preparations [PMID: 23090578]. This signaling cascade activates PI3K/Akt and MAPK/ERK, both of which are linked to neuronal survival signaling and dendritic spine remodeling in published literature. Bhatt et al. reported increased synaptic density markers in hippocampal preparations following Dihexa treatment in rodent models [PMID: 23548006]. The HGF/c-Met axis is also implicated in neuroprotection following ischemic insult in preclinical models. Dihexa's documented potency at this receptor system makes it a valuable pharmacological probe for synaptogenesis research. All uses of Dihexa are for preclinical research only.
How do researchers measure BDNF changes in Semax studies?
Published Semax research employs several methodologies to measure BDNF changes in preclinical models. ELISA-based protein quantification measures BDNF concentrations in conditioned cell culture media, tissue homogenates, and cerebrospinal fluid fractions from rodent models. Quantitative PCR methods measure BDNF mRNA transcript levels in neuronal cell preparations and brain tissue sections, enabling comparison of transcriptional induction across treatment conditions. Immunohistochemistry with anti-BDNF antibodies enables spatial localization of BDNF expression changes in specific brain regions such as hippocampus and cortex. Western blotting confirms mature BDNF protein levels alongside precursor proBDNF in tissue lysates. TrkB receptor phosphorylation assays — particularly phospho-TrkB ELISA and co-immunoprecipitation — confirm downstream receptor activation following BDNF induction, as characterized in the context of Semax treatment by Ashmarin et al. [PMID: 16445185]. Medvedeva et al. applied gene expression arrays to capture broader transcriptomic responses beyond BDNF alone [PMID: 18841466]. All measurement approaches are applied in preclinical or in vitro contexts; Semax is supplied by Evo Amino for research purposes only.
What research models are used to study Selank's anxiolytic properties?
Published research on Selank's anxiolytic properties primarily uses rodent behavioral paradigms combined with neurobiological readouts in animal models. The elevated plus maze quantifies anxiolytic-like behavior by measuring time spent in open versus closed arms. The open field test assesses locomotor activity and center-zone exploration frequency, behavioral measures that correlate with anxiety-like states in rodent models. Published studies by Kozlovskaya et al. and Kozlovsky et al. employed neurochemical endpoints including GABA-A receptor binding assays and enkephalin peptide quantification to establish mechanistic correlates of behavioral observations [PMID: 22786332] [PMID: 22968004]. Stress-induced hyperthermia models assess anxiolytic effects at the physiological level, complementing behavioral readouts. In vitro models complement behavioral work by enabling direct receptor binding measurements in neuronal cell preparations, isolating receptor-level mechanisms from whole-animal confounds. Uchakina et al. used immune cell culture systems to characterize Selank's immunomodulatory activity in parallel with behavioral studies [PMID: 20717095]. All models are preclinical; Selank is supplied by Evo Amino for research purposes only.
All compounds listed are for research purposes only. Evo Amino provides research-grade peptides intended for laboratory and preclinical research. Not for human or veterinary use.